RECRUITINGOBSERVATIONAL
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I
About This Trial
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Who May Be Eligible (Plain English)
Who May Qualify:
- Migraine with or without aura diagnosis according to ICHD-3 criteria
- \<8 migraine days per month
- Be able to read, write and understand instructions.
- Have internet access and mail address
- Signing of the willing to sign a consent form
Who Should NOT Join This Trial:
- Active preventive treatment for migraine
- Active medication with an effect over the central nervous system
- Serious physical or psychiatric condition
- Cardiovascular or hepatic disease
- Pregnant or breastfeeding women
- Any triptan contraindication
- Severe migraine attacks without previous response to triptans or NSAIDs
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Migraine with or without aura diagnosis according to ICHD-3 criteria
* \<8 migraine days per month
* Be able to read, write and understand instructions.
* Have internet access and mail address
* Signing of the informed consent
Exclusion Criteria:
* Active preventive treatment for migraine
* Active medication with an effect over the central nervous system
* Serious physical or psychiatric condition
* Cardiovascular or hepatic disease
* Pregnant or breastfeeding women
* Any triptan contraindication
* Severe migraine attacks without previous response to triptans or NSAIDs
Treatments Being Tested
DRUG
Sumatriptan
Register the response to treatment and headache characteristics.
Locations (1)
Hospital Universitari Vall d'Hebron
Barcelona, Spain